SCHEMBL1680341

SCHEMBL1680341

C[N]Cc1ccc2ccccc2c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.59
CYP1A2 P05177 2/20 0.59
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50
HTR2B P41595 1/20 0.50
SIGMAR1 Q99720 1/20 0.47
KMT2A Q03164 1/20 0.47
PYCR1 P32322 1/20 0.43
MC4R P32245 1/20 0.43
MC5R P33032 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
IDO1 P14902 1/20 0.42
ACHE P22303 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6008132 0.84 CYP1A2 (0.60) CYP2A6CYP1A2HTR2AHTR2CHTR2B
SCHEMBL8851214 0.79 CYP2A6 (0.61) CYP2A6CYP1A2HTR2AHTR2CHTR2B
SCHEMBL1680518 0.79 CYP1A2 (0.55) CYP2A6CYP1A2HTR2AHTR2CHTR2B
SCHEMBL8009667 0.78 CYP1A2 (0.54) CYP2A6CYP1A2HTR2AHTR2CHTR2B
SCHEMBL12630751 0.78 CYP1A2 (0.54) CYP2A6CYP1A2HTR2AHTR2CHTR2B
SCHEMBL8852228 0.78 HTR2A (0.55) CYP2A6CYP1A2HTR2AHTR2CHTR2B
SCHEMBL8851346 0.76 CYP2A6 (0.57) CYP2A6CYP1A2HTR2AHTR2CHTR2B
SCHEMBL8089570 0.75 CYP1A2 (0.50) CYP2A6CYP1A2HTR2AHTR2CHTR2B
SCHEMBL905392 0.75 CYP2A6 (0.60) CYP2A6CYP1A2HTR2AHTR2CHTR2B
SCHEMBL31355436 0.75 CYP2A6 (0.60) CYP2A6CYP1A2HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed
US-5618814-A Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds DR. KARL THOMAE GMBH (DE) 1997-04-08 US disclosed
EP-0645390-A1 Trisubstituted pyrimido 5,4-d pyrimidines for modulating multidrug resistance, drugs containing these compounds and processes for their preparation Dr. Karl Thomae GmbH (DE) 1995-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND ERG28, CYP51A1, XPO1 CYP2A6 1051/4885CYP1A2 147/4885HTR2A 3780/4885
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD CYP2A6 2188/4885CYP1A2 1886/4885HTR2A 3025/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 CYP2A6 1103/4885CYP1A2 187/4885HTR2A 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.